These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 26666596)

  • 1. Impact of Body Weight Reduction via Diet and Exercise on the Anti-Viral Effects of Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C Patients with Insulin Resistance: A Randomized Controlled Pilot Trial.
    Iwane S; Mizuta T; Kawaguchi Y; Takahashi H; Oza N; Oeda S; Nakashita S; Kuwashiro T; Otsuka T; Kawazoe S; Eguchi Y; Anzai K; Ozaki I; Fujimoto K
    Intern Med; 2015; 54(24):3113-9. PubMed ID: 26666596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients.
    Huang JF; Dai CY; Yu ML; Huang CF; Huang CI; Yeh ML; Yang JF; Hou NJ; Hsiao PJ; Lin ZY; Chen SC; Shin SJ; Chuang WL
    Liver Int; 2011 Sep; 31(8):1155-62. PubMed ID: 21745292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.
    Kim SR; Saito J; Imoto S; Komaki T; Nagata Y; Nakajima T; Ando K; Fukuda K; Otono Y; Kim KI; Ohtani A; Sugimoto K; Hasegawa Y; Fujinami A; Ohta M; Hotta H; Maekawa Y; Hayashi Y; Kudo M
    Digestion; 2011; 84 Suppl 1():5-9. PubMed ID: 22156479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients.
    Helal GK; Gad MA; Abd-Ellah MF; Mahgoup EM
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):553-7. PubMed ID: 26872109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
    Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
    Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.
    Yokoyama S; Takahashi S; Kawakami Y; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
    J Viral Hepat; 2014 May; 21(5):348-56. PubMed ID: 24716637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.
    Dai CY; Huang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
    J Hepatol; 2009 Apr; 50(4):712-8. PubMed ID: 19231011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
    Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
    [No Abstract]   [Full Text] [Related]  

  • 13. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.
    Hsu CS; Hsu SJ; Lin HH; Tseng TC; Wang CC; Chen DS; Kao JH
    J Formos Med Assoc; 2014 Oct; 113(10):716-21. PubMed ID: 24974131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.
    Aghemo A; Prati GM; Rumi MG; Soffredini R; D'Ambrosio R; Orsi E; De Nicola S; Degasperi E; Grancini V; Colombo M
    Hepatology; 2012 Nov; 56(5):1681-7. PubMed ID: 22619107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
    Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
    Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
    Pattullo V; Ravindran NC; Mazzulli T; Wong DK; Heathcote EJ
    J Viral Hepat; 2010 Dec; 17(12):834-8. PubMed ID: 20196800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
    Shirakawa H; Matsumoto A; Joshita S; Komatsu M; Tanaka N; Umemura T; Ichijo T; Yoshizawa K; Kiyosawa K; Tanaka E;
    Hepatology; 2008 Dec; 48(6):1753-60. PubMed ID: 18925643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.